Technical Analysis for CARA - Cara Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 6.14% | |
| Wide Range Bar | Range Expansion | 6.14% | |
| Down 3 Days in a Row | Weakness | 13.61% | |
| Fell Below 20 DMA | Bearish | 10.98% | |
| 20 DMA Support | Bullish | 8.31% | |
| NR7 | Range Contraction | 8.31% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Possible Pocket Pivot | about 6 hours ago | |
| 60 Minute Opening Range Breakdown | about 7 hours ago | |
| Gap Up Partially Closed | about 8 hours ago | |
| Upper Bollinger Band Resistance | about 8 hours ago | |
| 50 DMA Resistance | about 8 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/10/2020
- Sector: Healthcare
- Industry: Biotechnology
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Chemistry Biopharmaceutical Health Pain Clinical Trial Piperidines Amines Mesoblast
Chemistry Biopharmaceutical Health Pain Clinical Trial Piperidines Amines Mesoblast
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.67 |
| 52 Week Low | 8.88 |
| Average Volume | 402,853 |
| 200-Day Moving Average | 15.41 |
| 50-Day Moving Average | 14.76 |
| 20-Day Moving Average | 13.49 |
| 10-Day Moving Average | 13.90 |
| Average True Range | 0.63 |
| ADX | 23.17 |
| +DI | 31.49 |
| -DI | 20.59 |
| Chandelier Exit (Long, 3 ATRs ) | 13.34 |
| Chandelier Exit (Short, 3 ATRs ) | 14.19 |
| Upper Bollinger Band | 14.75 |
| Lower Bollinger Band | 12.24 |
| Percent B (%b) | 1.04 |
| BandWidth | 18.65 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.36 |
| MACD Histogram | 0.1969 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.50 | ||||
| Resistance 3 (R3) | 16.44 | 15.83 | 16.22 | ||
| Resistance 2 (R2) | 15.83 | 15.42 | 15.86 | 16.13 | |
| Resistance 1 (R1) | 15.35 | 15.16 | 15.05 | 15.41 | 16.04 |
| Pivot Point | 14.74 | 14.74 | 14.59 | 14.77 | 14.74 |
| Support 1 (S1) | 14.26 | 14.33 | 13.96 | 14.32 | 13.68 |
| Support 2 (S2) | 13.65 | 14.07 | 13.68 | 13.59 | |
| Support 3 (S3) | 13.17 | 13.65 | 13.50 | ||
| Support 4 (S4) | 13.23 |
